Plain-English translation of NCT04370587 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new medication called that is injected directly into tumors to help your immune system fight cancer. Researchers want to find the safest and most effective dose of this medication, and whether it works better when combined with a standard immunotherapy drug called pembrolizumab. The trial includes patients with several types of advanced cancers, including melanoma, head and neck cancer, sarcoma, lung cancer, and skin cancer.
Many patients with advanced cancers stop responding to standard treatments, and their cancer continues to grow. This medication is designed to work differently—by being injected directly into the tumor to trigger a strong local immune response. Researchers hope this approach may help patients whose cancer has become resistant to other therapies.
You likely qualify if…
You likely don't qualify if…
You will visit the clinic regularly for injections of the medication directly into your tumor. Depending on which part of the study you join, you may receive the medication alone or in combination with intravenous pembrolizumab. You will have blood tests, scans, and tumor biopsies taken to monitor how the treatment is working and any side effects. The study will track your health closely over several months to determine if this approach is safe and effective for your type of cancer.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States